The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Effectiveness of convalescent plasma therapy in severe COVID-19 patients
Open accessAbstract
Currently, there are no approved specific antiviral agents for novel coronavirus disease 2019 (COVID-19). In this study, 10 severe patients confirmed by real-time viral RNA test were enrolled prospectively. One dose of 200 mL of convalescent plasma (CP) derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to maximal supportive care and antiviral agents. The primary endpoint was the safety of CP transfusion. The second endpoints were the improvement of clinical symptoms and laboratory parameters within 3 d after CP transfusion. The median time from onset of illness to CP transfusion was 16.5 d. After CP transfusion, the level of neutralizing antibody increased rapidly up to 1:640 in five cases, while that of the other four cases maintained at a high level (1:640). The clinical symptoms were significantly improved along with increase of oxyhemoglobin saturation within 3 d. Several parameters tended to improve as compared to pretransfusion, including increased lymphocyte counts (0.65 × 10 9 /L vs. 0.76 × 10 9 /L) and decreased C-reactive protein (55.98 mg/L vs. 18.13 mg/L). Radiological examinations showed varying degrees of absorption of lung lesions within 7 d. The viral load was undetectable after transfusion in seven patients who had previous viremia. No severe adverse effects were observed. This study showed CP therapy was well tolerated and could potentially improve the clinical outcomes through neutralizing viremia in severe COVID-19 cases. The optimal dose and time point, as well as the clinical benefit of CP therapy, needs further investigation in larger well-controlled trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884 · cited 1×
“significantly higher than in those who did not require ICU conditions (2, 18).”
Self-citationA pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Self-citationChen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Self-citationWang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958
Self-citationFirst case of 2019 novel coronavirus in the United States
Holshue, M. L., DeBolt, C., Lindquist, S., Lofy, K. H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001191 · Cited by 6,030
Channappanavar, R., & Perlman, S. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0629-x · Cited by 2,524
Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury
Russell, C. D., Millar, J. E., & Baillie, J. K. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30317-2 · Cited by 2,008
World Health Organization (2020) · Pediatria i Medycyna Rodzinna · doi:10.15557/pimr.2020.0003 · Cited by 1,329
Drug treatment options for the 2019-new coronavirus (2019-nCoV)
Lu, H. (2020) · BioScience Trends · doi:10.5582/bst.2020.01020 · Cited by 1,133
Convalescent plasma as a potential therapy for COVID-19
Chen, L., Xiong, J., Bao, L., & Shi, Y. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30141-9 · Cited by 1,038
Self-citationMair-Jenkins, J., Saavedra-Campos, M., Baillie, J. K., Cleary, P., Khaw, F.-M., Lim, W. S., Makki, S., Rooney, K. D., Convalescent Plasma Study Group, Nguyen-Van-Tam, J. S., et al. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu396 · Cited by 983
Use of convalescent plasma therapy in SARS patients in Hong Kong
Cheng, Y., Wong, R., Soo, Y. O. Y., Wong, W. S., Lee, C. K., Ng, M. H. L., Chan, P., Wong, K. C., Leung, C. B., & Cheng, G. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1271-9 · Cited by 958
Hung, I. F., To, K. K., Lee, C.-K., Lee, K.-L., Chan, K., Yan, W.-W., Liu, R., Watt, C.-L., Chan, W.-M., Lai, K.-Y., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq106 · Cited by 678
On the use of corticosteroids for 2019-nCoV pneumonia
Shang, L., Zhao, J., Hu, Y., Du, R., & Cao, B. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30361-5 · Cited by 604
Self-citationEvaluation of Convalescent Plasma for Ebola Virus Disease in Guinea
van Griensven, J., Edwards, T., de Lamballerie, X., Semple, M. G., Gallian, P., Baize, S., Horby, P. W., Raoul, H., Magassouba, N., Antierens, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1511812 · Cited by 536
Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins
Wang, S.-F., Tseng, S.-P., Yen, C.-H., Yang, J.-Y., Tsao, C.-H., Shen, C.-W., Chen, K.-H., Liu, F.-T., Liu, W.-T., Chen, Y.-M. A., et al. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.07.090 · Cited by 421
Self-citationTreatment with Convalescent Plasma for Influenza A (H5N1) Infection
Zhou, B., Zhong, N., & Guan, Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmc070359 · Cited by 406
Disappearance of Antibodies to SARS-Associated Coronavirus after Recovery
Cao, W.-C., Liu, W., Zhang, P.-H., Zhang, F., & Richardus, J. H. (2007) · New England Journal of Medicine · doi:10.1056/nejmc070348 · Cited by 367
Dengue Antibody-Dependent Enhancement: Knowns and Unknowns
Halstead, S. B. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.aid-0022-2014 · Cited by 336
Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV
Lee, P.-I., & Hsueh, P.-R. (2020) · Journal of Microbiology, Immunology and Infection · doi:10.1016/j.jmii.2020.02.001 · Cited by 327
Ko, J.-H., Seok, H., Cho, S. Y., Ha, Y. E., Baek, J. Y., Kim, S. H., Kim, Y.-J., Park, J. K., Chung, C. R., Kang, E.-S., et al. (2018) · Antiviral Therapy · doi:10.3851/imp3243 · Cited by 323
Convalescent plasma: new evidence for an old therapeutic tool?
Marano, G., Vaglio, S., Pupella, S., Facco, G., Catalano, L., Liumbruno, G. M., & Grazzini, G. (2016) · PubMed · doi:10.2450/2015.0131-15 · Cited by 322
Yeh, K.-M., Chiueh, T.-S., Siu, L. K., Lin, J.-C., Chan, P. K. S., Peng, M.-Y., Wan, H.-L., Chen, J.-H., Hu, B.-S., Perng, C.-L., et al. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki346 · Cited by 247
Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia
Arabi, Y. M., Hajeer, A. H., Luke, T., Raviprakash, K., Balkhy, H., Johani, S., Al-Dawood, A., Al-Qahtani, S., Al-Omari, A., Al-Hameed, F., et al. (2016) · Emerging Infectious Diseases · doi:10.3201/eid2209.151164 · Cited by 244
Dissecting antibody-mediated protection against SARS-CoV-2
Zohar, T., & Alter, G. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0359-5 · Cited by 229
Transfusion‐related acute lung injury (TRALI): a clinical review with emphasis on the critically ill
Benson, A. B., Moss, M. M., & Silliman, C. C. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07840.x · Cited by 164
Treatment of severe acute respiratory syndrome with convalescent plasma.
Wong, V. W., Dai, D., Wu, A. K. L., & Sung, J. J. �. (2003) · PubMed · Cited by 142
COVID-19 infection: the China and Italy perspectives
Chen, J., Lu, H., Melino, G., Boccia, S., Piacentini, M., Ricciardi, W., Wang, Y., Shi, Y., & Zhu, T. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2603-0 · Cited by 139
Self-citationMora-Rillo, M., Arsuaga, M., Olivencia, G. R., Calle, F., Borobia, A. M., Sánchez-Seco, P., Lago, M., Figueira, J. C., Fernández-Puntero, B., Viejo, A., et al. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00180-0 · Cited by 128
Eickmann, M., Gravemann, U., Handke, W., Tolksdorf, F., Reichenberg, S., Müller, T. H., & Seltsam, A. W. (2018) · Transfusion · doi:10.1111/trf.14652 · Cited by 121
Passive antibody therapy in COVID-19
Abraham, J. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-0365-7 · Cited by 109
Karp, D. G., Danh, K., Fonseca, N., Seftel, D., Robinson, P. V., & Tsai, C. (2020) · Scientific Reports · doi:10.1038/s41598-020-76913-6 · Cited by 77
Successful treatment of avian influenza with convalescent plasma.
Kong, L.-B., & Zhou, B. P. (2006) · PubMed · Cited by 73
Treatment of severe acute respiratory syndrome with convalescent plasma.
Burnouf, T. P. R., & Radosevich, M. (2003) · PubMed · Cited by 47
Dengue Antibody-Dependent Enhancement: Knowns and Unknowns
Halstead, S. B. (2015) · ASM Press eBooks · doi:10.1128/9781555817411.ch15 · Cited by 39
Modeling serological testing to inform relaxation of social distancing for COVID-19 control
Kraay, A. N. M., Nelson, K., Zhao, C., Demory, D., Weitz, J. S., & Lopman, B. A. (2021) · Nature Communications · doi:10.1038/s41467-021-26774-y · Cited by 28
Info Guides: Coronavirus Disease (COVID-19): World Health Organization
Woroniak, M. (2020) · Cited by 27
Cited by
Characteristics of SARS-CoV-2 and COVID-19
Hu, B., Guo, H., Zhou, P., & Shi, Z.-L. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00459-7 · Cited by 5,291
Self-citationAutopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study
Wichmann, D., Sperhake, J.-P., Lütgehetmann, M., Steurer, S., Edler, C., Heinemann, A., Heinrich, F., Mushumba, H., Kniep, I., Schröder, A. S., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m20-2003 · Cited by 2,274
Immunology of COVID-19: Current State of the Science
Vabret, N., Britton, G. J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M. D., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.002 · Cited by 1,623
Self-citationBerlin, D. A., Gulick, R. M., & Martinez, F. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmcp2009575 · Cited by 1,439
Li, L., Zhang, W., Hu, Y., Tong, X., Zheng, S., Yang, J., Kong, Y., Ren, L., Wei, Q., Mei, H., et al. (2020) · JAMA · doi:10.1001/jama.2020.10044 · Cited by 1,206
Self-citation
Metadata
- Authors
- Duan, K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J., Zhou, M., Chen, L., Meng, S., Hu, Y., Peng, C., Yuan, M., Huang, J., Wang, Z., Yu, J., Gao, X., Wang, D., Yu, X., Li, L., Zhang, J., Wu, X., Li, B., Xu, Y., Chen, W., Peng, Y., Hu, Y., Lin, L., Liu, X., Huang, S., Zhou, Z., Zhang, L., Wang, Y., Zhang, Z., Deng, K., Xia, Z., Gong, Q., Zhang, W., Zheng, X., Liu, Y., Yang, H., Zhou, D., Yu, D., Hou, J., Shi, Z., Chen, S., Chen, Z., Zhang, X., & Yang, X.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2020-04-06
- Volume
- 117
- Issue
- 17
- Pages
- 9490-9496
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W3014735311
- Cited by
- 1,960
- References
- 37
- FWCI
- 56.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.